Parnax Lab Reports Stable Financial Performance and Improved Profitability Metrics in August 2025

Parnax Lab, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025, declared on August 13, 2025. The company has experienced a stable financial performance during this period. Notably, there has been an adjustment in its evaluation, with the score rising to 3 from 0 over the last three months. The financial data reveals that Parnax Lab achieved its highest operating profit to interest ratio in the last five quarters, recorded at 6.10 times. This indicates an enhancement in the company's capacity to manage its interest obligations effectively. Additionally, net sales reached Rs 53.38 crore, marking the highest figure in the same five-quarter timeframe, suggesting a positive trend in near-term sales. These developments reflect Parnax Lab's ongoing efforts to strengthen its financial standing within the competitive landscape of the pharmaceuticals and biotechnology industry. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.